Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial Infarction

New England Journal of Medicine

Volumn 321, Issue 6, 1989, Pages 406-412

  Engel, George L ^a  

^a CAST Coordinating Center 1107 NE 45th ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENCAINIDE; FLECAINIDE; MORACIZINE;

CLINICAL TRIAL; CONTROLLED STUDY; FATALITY; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUDDEN DEATH;

AGED; ANILIDES; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CARDIAC COMPLEXES, PREMATURE; CLINICAL TRIALS; DEATH, SUDDEN; ENCAINIDE; FEMALE; FLECAINIDE; FOLLOW-UP STUDIES; HUMAN; MALE; MIDDLE AGE; MORICIZINE; MYOCARDIAL INFARCTION; PHENOTHIAZINES; RANDOM ALLOCATION; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0024321898     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198908103210629     Document Type: Article

References (30)

1. Bigger JT Jr, Fleiss JL, Kleiger R, Miller JP, Rolnitzky LM, Multicenter Post-Infarction Research Group. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250–8.
2. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two year follow-up. Am J Cardiol 1984; 54: 31–6.
3. Vlay S. How the university cardiologist treats ventricular premature beats: a nationwide survey of 65 university medical centers. Am Heart J 1985; 110: 904–12.
4. The CAPS Investigators. The Cardiac Arrhythmia Pilot Study. Am J Cardiol 1986; 57: 91–5.
5. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988; 61: 501–9.
6. Greene HL, Richardson DW, Hallstrom AP, et al. Congestive heart failure after myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 393–8.
7. Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986; 8: 607–15.
8. Greene HL, Richardson DW, Barker AH, et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic (the Cardiac Arrhythmia Pilot Study). Am J Cardiol 1989; 63: 1–6.
9. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. Littleton, Mass.: PSG Publishing, 1985:213–39.
10. Pawitan Y, Hallstrom AP, CAST Investigators. Sequential monitoring scheme for Cardiac Arrhythmia Suppression Trial. Controlled Clinical Trials 1988; 9: 268. abstract.
11. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659–63.
12. Halperin M, Lan KKG, Ware JH, Johnson NJ, DeMets DL. An aid to data monitoring in long-term clinical trials. Controlled Clin Trials 1982; 3: 311–23.
13. Miller RG Jr. Simultaneous statistical inference. 2nd ed. New York: Springer-Verlag, 1981.
14. Cornfield J. A statistical problem arising from retrospective studies. In: Neyman J, ed. Proceedings of the Third Berkeley Symposium on Mathematical Statistics and Probability. Berkeley: University of California Press, 1956:133–48.
15. Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522–3.
16. Collaborative Group. Phenytoin after recovery from myocardial infarction: controlled trial in 568 patients. Lancet 1971; 2: 1055–7.
17. Peter T, Ross D, Duffield A, et al. Effect on survival after myocardial infarction of long-term treatment with phenytoin. Br Heart J 1978; 40: 1356–60.
18. Ryden L, Arnman K, Conradson TB, Hofvendahl S, Mortensen O, Smedgard P. Prophylaxis of ventricular tachyarrhythmias with intravenous and oral tocainide in patients with and recovering from acute myocardial infarction. Am Heart J 1980; 100: 1006–12.
19. Bastian BC, Macfarlane PW, McLauchlan JH, et al. A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J 1980; 100: 1017–22.
20. Chamberlain DA, Jewitt DE, Julian DG, Campbell RW, Boyle DM, Shanks RG. Oral mexiletine in high-risk patients after myocardial infarction. Lancet 1980; 2: 1324–7.
21. IMPACT Research Group. International mexiletine and placebo antiarrhythmic coronary trial. I. Report on arrhythmia and other findings. J Am Coll Cardiol 1984; 4: 1148–63.
22. Hugenholtz PG, Hagemeijer F, Lubsen J, Glazer B, Van Durme JP, Bogaert MG. One year follow-up in patients with persistent ventricular arrhythmias after myocardial infarction treated with aprindine or placebo. In: Sandöe E, Julian DG, Pell JW, eds. Management of ventricular tachycardia: role of mexiletine. Amsterdam: Excerpta Medica, 1978:572–8.
23. Gottlieb SH, Achuff SC, Mellits ED, et al. Prophylactic antiarrhythmic therapy of high-risk in survivors of myocardial infarction: lower mortality at 1 month but not at 1 year. Circulation 1987; 75: 792–9.
24. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol 1983; 52: 32C–36C.
25. Salerno DM. Antiarrhythmic drugs: 1987–1988. J Electrophysiol 1987; 1: 217–28, 300–19, 435–65, 1988; 2:55–87.
26. Meier P. Statistical analysis of clinical trials. In: Shapiro SH, Louis TA, eds. Clinical trials: issues and approaches. New York: Marcel Dekker, 1983:155–89.
27. Simon R. Patient subsets and variation in therapeutic efficacy. Br J Clin Pharmacol 1982; 14: 473–82.
28. Vaughan-Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984; 24: 129–47.
29. Soyka LF. Safety of encainide for the treatment of ventricular arrhythmias. Am J Cardiol 1986; 58: 96C–103C.
30. Morganroth J. Risk factors for the development of proarrhythmic events. Am J Cardiol 1987; 59: 32E–37E.